FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CTATEMENT	OE (CHANGES	IAI	BENEFICIAL	OWNEDSHIE
SIAIEMENI	OF (SHANGES	Ш	DENEFICIAL	CAMINERSUIL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(A) or (D)

D

D

D

Amount

6,934(1)

5,561(1)

4,416(1)

Price

\$38.19

\$38.19

\$38.86

OMB APPROVAL

3235-0287

(Instr. 4)

D

D

D

0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

Check this box if no longer subject to

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1(c). See Instru	iction 10.	-									
1. Name and Address of Reporting Person* Edris Badreddin (Last) (First) (Middle) C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD.				uer Name and Ticking Works The te of Earliest Transa 4/2025	erapeutics	, Inc. [SWTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) below) Chief Operating Officer				
(Street) STAMFORD (City)	CT (State)	06902 (Zip)	4. If A	mendment, Date of	Original Filed	I (Month/Day/Year)	6. Indiv Line)	ridual or Joint/Group Form filed by One Form filed by Mor Person	e Reporting Pers	son	
		Table I - Non	-Derivative S	ecurities Acq	uired, Dis	posed of, or Benef	icially	Owned			
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr.	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Code

 $F^{(1)}$

 $F^{(1)}$

F(1)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

Common Stock(1)

Common Stock

Common Stock

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person

/s/ Francis I. Perier, Jr. as Attorney-in Fact

01/07/2025

Reported

Transaction(s)

(Instr. 3 and 4)

202,666

197,105

192,689

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

01/04/2025

01/05/2025

01/06/2025

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.